Evicenter
Entyvio (vedolizumab) in Ulcerative colitis
Manufacturer
Takeda Pharmaceuticals U.S.A., Inc.
Prescribing information
Entyvio (opens in a new tab)
Questions
37
Last updated

All questions

Clinical trials: Entyvio (vedolizumab) in ulcerative colitis

6 questions · 2 sources

Study results

How well does Entyvio IV work by Week 6 in ulcerative colitis (GEMINI I)?

Applies to Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

Note: The Entyvio HCP site calls UC Trials I and II of the Prescribing Information the GEMINI I trial. Table 4 columns are placebo (N=149), ENTYVIO IV 300 mg (N=225), p-value, and treatment difference with 95% CI, in that order.

What were Entyvio IV Week 52 results in ulcerative colitis (GEMINI I)?

Applies to Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

“Table 5. Proportion of Patients Meeting Efficacy Endpoints at Week 52* (UC Trial II) Endpoint Placebo† N=126 ENTYVIO IV Every 8 Weeks N=122 p-value Treatment Difference and 95% CI Clinical Remission at Week 52 16% 42% <0.001 26% (15%, 37%) Clinical Response at both Weeks 6 and 52 24% 57% <0.001 33% (21%, 45%) Improvement of Endoscopic Appearance of the Mucosa‡ at Week 52 20% 52% <0.001 32% (20%, 44%) Clinical Remission at both Weeks 6 and 52 9% 21% 0.008 12% (3%, 21%) Corticosteroid-free Clinical Remission§ 14%§ 31%§ 0.012 18% (4%, 31%) * Patients must have achieved clinical response at Week 6 to continue into UC Trial II. This group includes patients that were not in clinical remission at Week 6. † The placebo group includes those patients who received ENTYVIO at Week 0 and Week 2 and were randomized to receive placebo from Week 6 through Week 52. ‡ Improvement of endoscopic appearance of the mucosa: Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild friability) at Week 52. § Corticosteroid-free clinical remission: Assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 for ENTYVIO every eight weeks). Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup that discontinued corticosteroids by Week 52 and were in clinical remission at Week 52.” (opens the source at this quote in a new tab)

Note: Only patients in clinical response at Week 6 after two ENTYVIO IV doses were randomized. Table 5 columns are placebo (N=126), ENTYVIO IV 300 mg every 8 weeks (N=122), p-value, and treatment difference with 95% CI, in that order; the every-4-week arm is not shown.

Does Entyvio help ulcerative colitis patients get off steroids (GEMINI I)?

Applies to Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

Note: Values are placebo (14%), ENTYVIO IV 300 mg every 8 weeks (31%), p-value, and treatment difference with 95% CI, at Week 52 in UC Trial II, in that order.

How well does subcutaneous Entyvio work for ulcerative colitis (VISIBLE 1)?

Applies to Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

“Table 6. Proportion of Patients Meeting Efficacy Endpoints at Week 52* (SC UC Trial) Endpoint Placebo† ENTYVIO 108 mg SC Every 2 Weeks‡ Estimate§ of Treatment Difference vs. Placebo (95% CI) Clinical Remission# at Week 52 Total Population N=56 14% N=106 46% 32 (20, 45) Prior TNF blocker failure N=20 10% N=40 35% Without prior TNF blocker failure N=36 17% N=66 53% Improvement of Endoscopic Appearance of the Mucosa at Week 52β Total Population N=56 21% N=106 57% 36 (22, 49) Prior TNF blocker failure N=20 10% N=40 48% Without prior TNF blocker failure N=36 28% N=66 62% Clinical Response at both Weeks 6 and 52¥ Total Population N=56 29% N=106 64% 36 (21, 51) Prior TNF blocker failure N=20 20% N=40 68% Without prior TNF blocker failure N=36 33% N=66 62% * Patients must have achieved clinical response at Week 6 to continue into SC UC Trial. † The placebo group includes those subjects who received intravenous vedolizumab at Week 0 and Week 2 and were randomized to receive placebo from Week 6 through Week 52. ‡ Starting at Week 6 following two intravenous doses of ENTYVIO 300 mg administered as an intravenous infusion at Weeks 0 and 2. § Estimated treatment difference is based on the Cochran-Mantel-Haenszel method. # Clinical remission: Complete Mayo score of ≤2 points and no individual subscore >1 point at Week 52. ¶ p <0.001 β Improvement of endoscopic appearance of the mucosa: Mayo endoscopic subscore of ≤1 point. ¥ Clinical response: reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.” (opens the source at this quote in a new tab)

Note: The Prescribing Information calls VISIBLE 1 the SC UC Trial (NCT02611830). Within each row of Table 6, the placebo N and percentage come first, then the ENTYVIO 108 mg subcutaneous every 2 weeks N and percentage, then the estimated treatment difference with 95% CI for the total population. The 64% versus 20% figure is for the subgroup in remission at Week 6; the efficacy page reports durable clinical remission for the overall population.

Comparative studies

Entyvio vs Humira: which had higher ulcerative colitis remission at Week 52 (VARSITY)?

Applies to Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

Note: The page labels the VARSITY comparison ENTYVIO IV vs Humira (adalimumab). The page states the endoscopic improvement and corticosteroid-free remission results without percentages and does not state which arm had the higher corticosteroid-free remission rate.

Outcome measures

How is ulcerative colitis remission defined in Entyvio trials (Mayo score)?